Microbiome Research Converges on Hidden Gut Bacteria, Infant Allergy Prevention, and Cancer Immunotherapy
A Cambridge-led study identifies CAG-170 bacteria as a global marker of gut health, Siolta Therapeutics reports a 64 percent reduction in infant atopic dermatitis risk, and UF Health isolates a bacterial metabolite that doubles lung cancer immunotherapy response in mice.
A Hidden Bacterial Group Tied to Health Worldwide
A previously overlooked group of gut bacteria called CAG-170 appears at consistently higher levels in healthy people than in those with chronic diseases, according to a University of Cambridge study published in Cell Host & Microbe on February 9, 2026. The research team, led by Dr. Alexandre Almeida of Cambridge’s Department of Veterinary Medicine, analyzed 11,115 gut microbiome samples from 39 countries using the Unified Human Gastrointestinal Genome catalogue, which contains more than 4,600 bacterial species.
CAG-170 levels were significantly lower in individuals with 13 conditions, including inflammatory bowel disease, colorectal cancer, obesity, Parkinson’s disease, and multiple sclerosis, according to ScienceDaily. The bacteria have never been successfully cultured in a laboratory, meaning they are known only from their genetic fingerprints in metagenomic data.
Further genomic analysis revealed that CAG-170 bacteria produce high levels of vitamin B12 and enzymes capable of breaking down a wide range of carbohydrates, sugars, and dietary fibers. The researchers believe the B12 production likely supports neighboring bacterial species rather than the human host directly. “These are a fundamental and underappreciated component of human health,” Almeida said, as quoted by the University of Cambridge.
The findings suggest CAG-170 could serve as a biomarker for gut microbiome health and potentially inform the development of next-generation probiotics designed to restore or maintain the group’s presence.
Infant Microbiome Therapy Cuts Allergy Risk
Siolta Therapeutics, a UCSF spinout, reported positive Phase 2 results from its ADORED trial (Allergic Disease Onset pREvention stuDy) of STMC-103H, an oral microbial therapy designed to prevent atopic diseases in at-risk infants. Among 238 newborns enrolled across 30 sites in the United States and Australia, infants who completed one year of treatment showed a 64 percent reduction in the risk of physician-diagnosed atopic dermatitis (23.3 percent versus 43.1 percent; p=0.005) and a 77 percent reduction in food allergy risk (4.7 percent versus 16.7 percent; p=0.02), according to the company’s press release.
STMC-103H contains a defined set of bacterial strains naturally found in healthy infants, intended to work synergistically during the first year of life to shape immune development. The therapy was well-tolerated, with no significant differences in serious adverse events between the treatment and placebo groups. The results were presented as a late-breaking oral abstract at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia on February 28, 2026. Year 2 follow-up data are expected in the first quarter of 2026.
The trial represents one of the first rigorous demonstrations that early-life microbiome intervention can meaningfully reduce the incidence of allergic disease, an area of growing clinical interest as atopic conditions continue to rise globally.
Bacterial Metabolite Doubles Cancer Immunotherapy Response
Researchers at the UF Health Cancer Institute have identified a naturally occurring bacterial metabolite called Bac429 that doubled the response to lung cancer immunotherapy in mice, according to UF Health. The study, published in Cell Reports Medicine on December 19, 2025, was led by Christian Jobin, the Gatorade Distinguished Professor of Medicine, and first author Rachel Newsome.
The team began by transplanting fecal samples from human patients who responded to immunotherapy into mice that did not respond to treatment. The mice then began responding to immunotherapy. From there, the researchers screened more than 180 bacterial strains and identified six that boosted treatment response. They then isolated Bac429 as the single metabolite responsible for the immune-stimulating effect. When injected into tumors of mice with highly nonresponsive lung cancer, Bac429 reduced tumor growth by 50 percent following immunotherapy.
The finding addresses a significant unmet need. Across all cancers, only about 20 percent of patients who receive immune checkpoint inhibitors respond to them. Jobin and Newsome have formed Bebi Therapeutics Inc. as a university spinout to develop drug derivatives of Bac429 for human clinical testing.
A Converging Field
Taken together, these three developments illustrate how microbiome science is advancing simultaneously on multiple fronts: fundamental biology through the Cambridge CAG-170 work, preventive medicine through Siolta’s infant allergy trial, and oncology through UF Health’s Bac429 research. The microbiome therapeutics market is projected to reach 7.16 billion dollars by 2036, according to industry estimates, driven in part by more than 140 companies and 180 drugs currently in development. Whether these laboratory and early-clinical results translate into approved therapies will depend on larger trials and the field’s ability to address the challenge of culturing and manufacturing organisms that, like CAG-170, have so far resisted laboratory cultivation.